Sun Pharma settles patent litigation with Acorda Therapeutics
NEW DELHI: Sun Pharma has settled a patent litigation with US-based Acorda Therapeutics Inc over Ampyra extended-release tablets, which is used in the treatment of multiple sclerosis patients.
As per the settlement the Indian drug major can launch its generic version of the medicine in the US by 2027.
"The company, along with its subsidiary has entered into a settlement agreement with Acorda Therapeutics Inc to resolve the pending patent litigation involving Ampyra extended release tablets in the US," Sun Pharmaceutical Industries said in a regulatory filing.
Ampyra is used to improve walking in patients with multiple sclerosis (MS).
The litigation was filed by Acorda Therapeutics in the US District Court of Delaware in response to Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration, seeking marketing approval for a generic version of Ampyra.
"As a result of the settlement agreement, Sun Pharma will be permitted to market a generic version of Ampyra in the US at a specified date in 2027, or potentially earlier under certain circumstances," the company said.
Details of the settlement are confidential, and the parties will submit the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law, it added.
As per IMS MAT July 2015 sales data, Ampyra recorded annual sales of around $325 million in the US.
As per the settlement the Indian drug major can launch its generic version of the medicine in the US by 2027.
"The company, along with its subsidiary has entered into a settlement agreement with Acorda Therapeutics Inc to resolve the pending patent litigation involving Ampyra extended release tablets in the US," Sun Pharmaceutical Industries said in a regulatory filing.
Ampyra is used to improve walking in patients with multiple sclerosis (MS).
The litigation was filed by Acorda Therapeutics in the US District Court of Delaware in response to Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration, seeking marketing approval for a generic version of Ampyra.
"As a result of the settlement agreement, Sun Pharma will be permitted to market a generic version of Ampyra in the US at a specified date in 2027, or potentially earlier under certain circumstances," the company said.
Details of the settlement are confidential, and the parties will submit the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law, it added.
As per IMS MAT July 2015 sales data, Ampyra recorded annual sales of around $325 million in the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.